These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 35501101)

  • 1. Motivations for concurrent use of uppers and downers among people who access harm reduction services in British Columbia, Canada: findings from the 2019 Harm Reduction Client Survey.
    Steinberg A; Mehta A; Papamihali K; Lukac CD; Young S; Graham B; Lock K; Fleury M; Buxton JA
    BMJ Open; 2022 May; 12(5):e060447. PubMed ID: 35501101
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Correlates of concurrent use of stimulants and opioids among people who access harm reduction services in British Columbia, Canada: Findings from the 2019 Harm Reduction Client Survey.
    Lukac CD; Steinberg A; Papamihali K; Mehta A; Lock K; Buxton JA
    Int J Drug Policy; 2022 Apr; 102():103602. PubMed ID: 35124412
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identifying behaviours for survival and wellness among people who use methamphetamine with opioids in British Columbia: a qualitative study.
    Corser J; Palis H; Fleury M; Lamb J; Lock K; McDougall J; Mehta A; Newman C; Spence H; Buxton JA
    Harm Reduct J; 2022 May; 19(1):46. PubMed ID: 35590375
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Convenience and comfort: reasons reported for using drugs alone among clients of harm reduction sites in British Columbia, Canada.
    Papamihali K; Yoon M; Graham B; Karamouzian M; Slaunwhite AK; Tsang V; Young S; Buxton JA
    Harm Reduct J; 2020 Nov; 17(1):90. PubMed ID: 33228676
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Factors associated with obtaining prescribed safer supply among people accessing harm reduction services: findings from a cross-sectional survey.
    Palis H; Haywood B; McDougall J; Xavier CG; Desai R; Tobias S; Burgess H; Ferguson M; Liu L; Kinniburgh B; Slaunwhite AK; Crabtree A; Buxton JA
    Harm Reduct J; 2024 Jan; 21(1):5. PubMed ID: 38184576
    [TBL] [Abstract][Full Text] [Related]  

  • 6. "It's just a perfect storm": Exploring the consequences of the COVID-19 pandemic on overdose risk in British Columbia from the perspectives of people who use substances.
    Foreman-Mackey A; Xavier J; Corser J; Fleury M; Lock K; Mehta A; Lamb J; McDougall J; Newman C; Buxton JA
    BMC Public Health; 2023 Apr; 23(1):640. PubMed ID: 37013524
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Acceptability of technological solutions for overdose monitoring: Perspectives of people who use drugs.
    Tsang VWL; Papamihali K; Crabtree A; Buxton JA
    Subst Abus; 2021; 42(3):284-293. PubMed ID: 31657675
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Associations with experience of non-fatal opioid overdose in British Columbia, Canada: a repeated cross sectional survey study.
    Ferguson M; Choisil P; Lamb J; Burmeister C; Newman C; Lock K; Tobias S; Liu L; Buxton JA
    Harm Reduct J; 2023 Dec; 20(1):178. PubMed ID: 38093272
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Crystal methamphetamine use in British Columbia, Canada: A cross-sectional study of people who access harm reduction services.
    Papamihali K; Collins D; Karamouzian M; Purssell R; Graham B; Buxton J
    PLoS One; 2021; 16(5):e0252090. PubMed ID: 34038452
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Distribution of take-home opioid antagonist kits during a synthetic opioid epidemic in British Columbia, Canada: a modelling study.
    Irvine MA; Buxton JA; Otterstatter M; Balshaw R; Gustafson R; Tyndall M; Kendall P; Kerr T; Gilbert M; Coombs D
    Lancet Public Health; 2018 May; 3(5):e218-e225. PubMed ID: 29678561
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Motivators of and barriers to drug checking engagement in British Columbia, Canada: Findings from a cross-sectional study.
    Tobias S; Ferguson M; Palis H; Burmeister C; McDougall J; Liu L; Graham B; Ti L; Buxton JA
    Int J Drug Policy; 2024 Jan; 123():104290. PubMed ID: 38101275
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Methamphetamine use in the United States: epidemiological update and implications for prevention, treatment, and harm reduction.
    Jones CM; Houry D; Han B; Baldwin G; Vivolo-Kantor A; Compton WM
    Ann N Y Acad Sci; 2022 Feb; 1508(1):3-22. PubMed ID: 34561865
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Motivation and context of concurrent stimulant and opioid use among persons who use drugs in the rural United States: a multi-site qualitative inquiry.
    Fredericksen RJ; Baker R; Sibley A; Estadt AT; Colston D; Mixson LS; Walters S; Bresett J; Levander XA; Leichtling G; Davy-Mendez T; Powell M; Stopka TJ; Pho M; Feinberg J; Ezell J; Zule W; Seal D; Cooper HLF; Whitney BM; Delaney JAC; Crane HM; Tsui JI
    Harm Reduct J; 2024 Apr; 21(1):74. PubMed ID: 38561753
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Implementation of Safe Supply Alternatives During Intersecting COVID-19 and Overdose Health Emergencies in British Columbia, Canada, 2021.
    McNeil R; Fleming T; Mayer S; Barker A; Mansoor M; Betsos A; Austin T; Parusel S; Ivsins A; Boyd J
    Am J Public Health; 2022 Apr; 112(S2):S151-S158. PubMed ID: 35262376
    [No Abstract]   [Full Text] [Related]  

  • 15. Feeling safer: effectiveness, feasibility, and acceptability of continuous pulse oximetry for people who smoke opioids at overdose prevention services in British Columbia, Canada.
    Moe J; Chavez T; Marr C; Cameron F; Feldman-Kiss D; Wang YE; Xavier JC; Mamdani Z; Purssell RA; Salmon A; Buxton JA
    Harm Reduct J; 2024 Feb; 21(1):45. PubMed ID: 38378610
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Housing and overdose: an opportunity for the scale-up of overdose prevention interventions?
    Bardwell G; Collins AB; McNeil R; Boyd J
    Harm Reduct J; 2017 Dec; 14(1):77. PubMed ID: 29212507
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Correlates of take-home naloxone kit possession among people who use drugs in British Columbia: A cross-sectional analysis.
    Moustaqim-Barrette A; Papamihali K; Crabtree A; Graham B; Karamouzian M; Buxton JA
    Drug Alcohol Depend; 2019 Dec; 205():107609. PubMed ID: 31654839
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Examining prevalence and correlates of smoking opioids in British Columbia: opioids are more often smoked than injected.
    Parent S; Papamihali K; Graham B; Buxton JA
    Subst Abuse Treat Prev Policy; 2021 Oct; 16(1):79. PubMed ID: 34663374
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Concurrent use of opioids and stimulants and risk of fatal overdose: A cohort study.
    Palis H; Xavier C; Dobrer S; Desai R; Sedgemore KO; Scow M; Lock K; Gan W; Slaunwhite A
    BMC Public Health; 2022 Nov; 22(1):2084. PubMed ID: 36380298
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Smoking identified as preferred mode of opioid safe supply use; investigating correlates of smoking preference through a 2021 cross-sectional study in British Columbia.
    Kamal A; Ferguson M; Xavier JC; Liu L; Graham B; Lock K; Buxton JA
    Subst Abuse Treat Prev Policy; 2023 May; 18(1):27. PubMed ID: 37194018
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.